Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs
This move is accompanied by a commitment to limit out-of-pocket costs for these insulin products to $35 or less starting January 1, potentially impacting the market dynamics for these pharmaceutical companies.“I’ve seen firsthand how high prices for insulin and other necessary medications can cause patients to limit or skip doses,” said Dr. Patrick Conway, chief executive officer of Optum Rx.
“Medicine that people can’t afford is useless, and by taking this important next step to change our formulary, we will lower costs and improve access for more people who need this life-saving medication. Our goal is to make all essential medicines affordable.” Today, over 70% of Optum Rx users pay less than $35 monthly for insulin. With the recent actions undertaken by Optum Rx, it is anticipated that 98% of all Optum Rx consumers will have access to insulin at a cost of $35 or less per month.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Zepbound is Eli Lilly’s new weight loss drug: What to knowBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Weiterlesen »
Eli Lilly Gets FDA Nod for Diabetes/Weight Loss DrugA new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.The U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide.
Weiterlesen »
What to Know about Eli Lilly's New Obesity DrugThe U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy. The once-weekly injection, which contains the same active ingredient as Lilly's...
Weiterlesen »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Weiterlesen »
Eli Lilly gets FDA approval for new obesity drugZepbound helped patients lose up to 48 pounds on average in clinical trials
Weiterlesen »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Weiterlesen »